Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

1(20%)

Results Posted

50%(1 trials)

Terminated

1(20%)

Phase Distribution

Ph phase_2

20%

Ph phase_1

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

2(66.7%)

Phase 2Efficacy & side effects

1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(2)

Terminated(1)

Other(1)

Detailed Status

Completed2

Terminated1

Recruiting1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (66.7%)

Phase 21 (33.3%)

Trials by Status

terminated120%

completed240%

recruiting120%

unknown120%

Recent Activity

1 active trials

Showing 5 of 5

recruiting

PrEPared to Choose (PtC) is an Implementation Study of the Delivery of Cabotegravir Long-acting, an Injectable Pre-exposure Prophylaxis (PrEP) Option for HIV Prevention. Injectable PrEP Will be Offered Alongside Oral and Vaginal Ring PrEP From Within a Real-world Context in Cape Town, South Africa.

NCT06807736

terminatedphase_2

Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B

NCT00524173

completedphase_1

SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women

NCT02499874

unknownphase_1

Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid

NCT02832778

completed

Single Dose Truvada in HIV-negative Men and Women

NCT01326221

Clinical Trials (5)

Showing 5 of 5 trials

NCT06807736

PrEPared to Choose (PtC) is an Implementation Study of the Delivery of Cabotegravir Long-acting, an Injectable Pre-exposure Prophylaxis (PrEP) Option for HIV Prevention. Injectable PrEP Will be Offered Alongside Oral and Vaginal Ring PrEP From Within a Real-world Context in Cape Town, South Africa.

Recruiting

NCT00524173Phase 2

Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B

Terminated

NCT02499874Phase 1

SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women

Completed

NCT02832778Phase 1

Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid

Unknown

NCT01326221

Single Dose Truvada in HIV-negative Men and Women